Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 5Recurrence 3Optic Neuritis 3Neuromyelitis Optica 3Myelitis, Transverse 3Demyelinating Diseases 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × eculizumab × Clear all
NCT04155424 2024-09-25

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

Alexion Pharmaceuticals, Inc.

Phase 2/3 Terminated
5 enrolled 15 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

NCT02003144 2022-08-23

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
119 enrolled 17 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

NCT01892345 2019-06-26

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Alexion Pharmaceuticals, Inc.

Phase 3 Terminated
143 enrolled 18 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡